Menu
← Oncology Approval Tracker
FDA DECISION ·
Keytruda
pembrolizumab · Merck Sharp & Dohme
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adults and children with unresectable or metastatic solid tumors with at least 10 mutations per megabase on an FDA-approved test, following progression on prior treatment when no satisfactory alternatives remained.
LAMPGEN ANALYSIS
Why it matters
Made tumor mutational burden a cross-tumor selection marker for immunotherapy under accelerated approval.
What research teams should watch
Record the assay, measured burden, prior treatment and available alternatives before matching the historical label.
PRIMARY RECORDS